Brd7 Antibodies

Bromodomain-containing protein 7 (Brd7)

Acts both as coactivator and as corepressor. May play a role in chromatin remodeling.

Transcriptional corepressor which down-regulates the expression of target genes. Binds to target promoters, resulting in increased histone H3 acetylation at'Lys-9' (H3K9ac).

Gene Information

Mouse
Gene Name:	Brd7
Uniprot:	O88665
Entrez:	26992

Family

Belongs to:
No superfamily

Alternative Names

75 kDa bromodomain protein; BP75bromodomain-containing 7; bromodomain containing 7; bromodomain-containing protein 7; CELTIX1NAG4; Protein CELTIX-1

Molecular Weight

Mass (kDA):
74 kDA

Genomic Context

Mouse
Location:	8|8 C3
Sequence:	8;

Tissue Specificity

Ubiquitous.

Diseases

• Carcinoma
• Cancer Of Nasopharynx
• Neoplasms
• Malignant Neoplasms
• Nasopharyngeal Neoplasms
• Neoplasm Metastasis
• Mammary Neoplasms
• Malignant Neoplasm Of Breast
• Cell Invasion
• Cell Transformation, Neoplastic
• Leukemia
• Colorectal Neoplasms

• Carcinogenesis
• Colorectal Cancer
• Right-sided Displacement Of Abomasum
• Stomach Neoplasms
• Metastatic Malignant Neoplasm To The Lymph Node
• Glioma
• Hiv/aids And Infections

Pathways

• Cell Cycle
• Cell Growth
• Pathogenesis
• Chromatin Remodeling
• Cell Proliferation
• Localization
• S Phase
• Senescence
• Histone Acetylation
• Oncogene-induced Senescence
• Dna Repair
• Demethylation
• Methylation

• Transport
• Osteoblast Differentiation
• Cellular Senescence
• Aging
• Histone Modification
• Replicative Senescence
• Cell Differentiation

PTMs

• Acetylation
• Demethylation

• Methylation
• Phosphorylation

• Dephosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/Brd7

Best Uses Of The BRD7 Marker From Boster Bio

Boster Bio has primary antibodies that have high-affinity against the BRD7 Marker. Their antibodies are highly cited over the past 25 years and have been validated on immunohistochemistry, Western Blotting, and ELISA. You can use them in your experiments with confidence. Visit their website to find out more about these antibodies.

Boster provides high-affinity primary antibody

Boster Bio has high-affinity primary antibodies against the BRD7 marker. This will give high-quality results from immunoassays. Designed for use in immunohistochemistry, these antibodies can be used in a wide variety of applications. These antibodies are highly effective for detecting BRD7 within cell membranes. The antibodies were also examined for cMyc binding in cell membranes.

The BRD7 gene was thoroughly researched to create the antibody. Then, the target protein was expressed in E. Coli using a prokaryotic-based expression system. After inducing the expression of recombinant proteins at 37C for 3.5 hours The purified proteins proved to be immunogenic in rabbits. They produced polyclonal antibody and were purified using a GST Sepharose4B affinity chromatography column to confirm their specificity. The antibody was tested for specificity and sensitivity using Western Blot and ELISA results.

BRD7 interacts with YB1 within HEK293T cell lines. This allows it to regulate the growth of cells, metastasis and metastasis. By preventing the expression of ectopic BRD7, YB1 expression was decreased in these cells. Restoring BRD7 in mice prevented the apoptosis process and restored YB1.

In addition to interacting with YB1 BRD7 also hinders the growth of tumors and their migration. It blocks the action of YB1 to prevent metastasis and growth of breast cancer. It also has a crucial role in tumorigenesis. Its lack of expression is associated with distant metastasis, advanced TNM stage and low levels of expression. Understanding the malignant features of BRD7 could help in developing personalized treatment options for breast cancer patients.

In addition to inhibiting the migration of breast cancer cells BRD7 also blocks cell invasion and cell migration. It also co-localizes with YB1 however it does not alter its protein or mRNA levels. BRD7 blocks YB1 expression by inhibiting its phosphorylation Ser102. In addition, it inhibits the activity of YB1 through proteasomal degradation.

Boster Bio provides primary antibodies against the BRD7 marker, which allow researchers to analyze the tissue distribution. They identify the BRD7 protein that is expressed by the body in the brain, pancreas kidney, lung, and cerebellum of human fetuses. In addition, BRD7 antibodies are useful for studies studying the bio-functions of endogenously expressed BRD7 protein.

High-affinity primary antibody against the BRD-7 marker has excellent affinity for binding to the N-terminal region of YB1. They can be useful in determining the phosphorylation status and function of YB1's DNA binding capabilities. Antibodies against the BRD7 marker can detect the BRD7 protein in cells.

In addition to its adaptive and innate immune system functions, BRD7 is involved in breast cancer. BRD7 inhibition in MDA231 breast carcinoma cells resulted in a reduction in cell growth and a reduction in their invasion and migration. Furthermore, BRD7 plays an important role in the NFKB pathway and in the production of p65 and iNOS.

Secondary antibodies are also available. Secondary antibodies can be used to label specimens using an antibody. Primary antibodies can be used as monoclonal or polyclonal. Secondary antibodies can be mixed with other compounds. Flow cytometry uses antibodies that are highly specific and high-affinity. This lets researchers identify the BRD7 marker within the sample.

BRD7 does not only impact cell migration and invasion but also influences other molecules involved with EMT. Moreover, overexpression of BRD7 decreased the amount of Snail and increased the expression of E-cadherin and Claudin1. In MDA231 cell lines, however, BRD7 knockdown produced a different result: vimentin's protein expression decreased, and BRD7 depletion promoted it.

The monoclonal antibody c-Myc recognizes the ectopically expressed Myc protein. It also recognizes the weak endogenous BRD7 proteins. In the Western blot assay, one band is visible. Two bands may represent phosphorylation, post-translational modifications or splice variants the BRD7 gene.

BRD7 and YB1 are not negatively related in breast cancer patients. Patients who had higher YB1 expression had worse outcomes in clinical trials than those who had lower BRD7 expression. Additionally, BRD7 expression was linked to distant metastatic disease, TNM stage ER, PR and YB1 levels. Low expression of either gene can result in poor prognosis.

Monoclonal antibodies are extremely specific and specific to their target antigens. Primary antibodies originate from host animals' immune systems. Utilizing antigens, scientists immunize animals and extract antibodies from egg or serum. They can detect, measure, purify and purify antibodies in this way. There is no other antibody on the market with such high affinity and specificity.

A study was conducted using two rabbits immunized with GST-BRD7N purified protein. After 25 days of the initial injection, antisera containing BRD7 antibody was obtained. Sera were used for the analysis of the specific anti-BRD7N antibody. A negative control was performed using rabbit serum that was preimmunized. The results of these experiments are shown below.

GenePharma, an Chinese company, obtained YB1 overexpressing the lentivirus from Sino biological in Beijing, China. This lentivirus carried a BRD7 shRNA sequence 5'-GUGCCAAGAUUAUTdT-3'. The supernatant of the virus was filtered by a 0.22 mm membrane. For 48 hours, the tumor cells were infected.